Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly
Phase 3
Completed
- Conditions
- Delirium
- Registration Number
- NCT00873379
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
122 people over 70 who were admitted to hospital were enrolled to the study. Half got .5 mg a night of melatonin, half got a placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 122
Inclusion Criteria
- Age over 65 admitted through the emergency department to an internal medicine service in London, Ontario, Canada.
Exclusion Criteria
- Life expectancy less than 24 hours,
- Unable to communicate in English,
- Unable to take oral medications,
- Intracranial bleed or known seizure disorder,
- Markedly sub or supra-therapeutic INR while on warfarin, OR
- A known allergy to study tablet ingredients.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method delirious using confusion assessment method (CAM) days
- Secondary Outcome Measures
Name Time Method MDAS (memorial delirium assessment scale) days
Trial Locations
- Locations (1)
London Health Sciences Centre
🇨🇦London, Ontario, Canada
London Health Sciences Centre🇨🇦London, Ontario, Canada